Answers are grounded in this paper and cite their sources.
Synthetic atrial natriuretic factor acts as a potent vasorelaxant through the elevation of cyclic GMP via particulate guanylate cyclase activation, exhibiting species and regional variations.
Synthetic atrial natriuretic factor (ANF) has been found to be a potent relaxant of isolated vascular preparations. ANF is more effective in relaxing agonist-induced versus depolarized contractile events and the relaxation efficacy appears inversely related to the level of contractile preload. The vasorelaxation to ANF is associated with elevations of cyclic GMP via an activation of the particulate form of guanylate cyclase. Both species and regional-vascular differences exist, in vitro as well as in vivo, in the vasorelaxation response to ANF which may reflect an altered distribution of high affinity receptors and/or different states of active vascular tone of the particular preparation.
No takes yet. Share an insight, caveat, or question.
Raymond J. Winquist (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: